Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

New Focus on Drug Safety Slows Drug Approvals

Posted by Jane Akre
Thursday, May 29, 2008 12:17 AM EST
Category: Major Medical, Protecting Your Family
Tags: FDA and Prescription Drugs, Vioxx, Merck, Dangerous Drugs

The FDA is getting more resources to do its job.

LEARN MORE

 

IMAGE SOURCE: Wikimedia Commons/ tablets/ author: Ragesoss

 

As regulators work to impose requirements meant to minimize the side effects of medications, a new focus on drug safety is delaying the approval of some new medicines.

In an effort to improve drug safety oversight, last year, Congress passed a new law giving the FDA more money and authority over drugmakers.

“That’s taking a considerable amount of time on every new application. The process will streamline and go away over time,” according to a statement Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, in an interview with Reuters.

Generally speaking, drug decision dates come six or ten months after a drugmaker has filed an application and are considered goals but not solid deadlines. Managers have been granted discretion to miss some drug approval dates if needed.

Since March, the agency has been hiring more staff to go through the backlog of new drug applications. 

Industry analysts speculated Woodstock’s return to lead up the FDA’s drug division would help move along drug approvals after what many saw as a slowdown following Merck & Co’s 2004 withdrawal of the popular arthritis drug, Vioxx. 

The FDA has been criticized as being slow to respond to problems with medications such as Vioxx, which Merck withdrew after research discovered the drug more than doubled heart attack and stroke risk in patients.

Following the revelation that a Chinese plant that made contaminated heparin had never been inspected, Janet Woodcock announced, earlier this month, that there were 332 inspections of foreign plants in 2007, more than ever before in agency history.   

The FDA is concerned about clinical trials being conducted outside of the U.S., but has not  allocated more funding for clinical trial inspections.  

A report issued late last year by an expert panel concludes that the FDA, so often portrayed as the final safety net that ensures the safety of the American food and drug supply, is broken.

The 56-page report entitled,  "FDA Science and Mission at Risk,"  basically concludes that the agency is putting American lives at risk by cutting inspectors overseas and domestically. It called on Congress to increase funding to the FDA.    # 


No Comments

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address

Subscribe

RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes